AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

The CAPItello-281 trial aimed to assess the safety and efficacy of Truqap in combination with abiraterone and ADT.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of ...

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of ...

High-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen ...